Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Metastatic sarcomas often exhibit resistance to conventional chemotherapy.
• The mammalian target of rapamycin (mTOR) pathway is crucial for cancer cell growth and proliferation.
• mTOR inhibitors represent a promising therapeutic strategy for various cancers, including sarcomas.

Purpose of the Study:

• To investigate if phosphorylated S6 ribosomal protein (pS6) expression can predict clinical response to the mTOR inhibitor AP23573 in patients with metastatic sarcomas.
• To evaluate pS6 as a potential predictive biomarker for targeted mTOR inhibitor therapy.

Main Methods:

• A blinded study was conducted on 20 patients with metastatic sarcomas treated with AP23573 (alone or with adriamycin).
• Tumor samples were stained for pS6 using immunohistochemistry.
• Staining quantity (high vs. low expressors) was correlated with clinical response (stable disease vs. progressive disease).

Main Results:

• High pS6 expression (≥20% of tumor cells) was observed in 11 patients, with 73% achieving stable disease.
• Low pS6 expression (0-10% of tumor cells) was observed in 9 patients, with 67% experiencing progressive disease.
• Statistical analysis revealed a significant correlation between pS6 expression levels and early tumor response to AP23573 (P<0.05).

Conclusions:

• Phosphorylated S6 ribosomal protein expression is a predictive marker for early tumor response in metastatic sarcoma patients treated with mTOR inhibitors.
• This finding supports the use of pS6 as a biomarker to guide targeted mTOR inhibitor therapy in sarcoma.
• Further research is warranted to validate pS6 as a predictive biomarker in broader patient populations.